Oneness Biotech Co., Ltd.

The Phase 3 MRCT post-hoc analysis and the post-market hard-to-heal cases of the DFU new drug, Fespixon have been accepted for an oral presentation at EWMA 2023.

2023-05-02

Statement
No	2	Date of announcement	2023/05/02	Time of announcement	17:53:30
Subject	The Phase 3 MRCT post-hoc analysis and the post-market hard-to-heal cases of the DFU new drug, Fespixon have been accepted for an oral presentation at EWMA 2023.
To which item it meets	paragraph 12			Date of events	2023/05/05
Date of institutional investor conference:2023/05/05 Time of institutional investor conference:19:30 (TPE time) Location of institutional investor conference:Milan, Italy Outline of institutional investor conference: (1)The Phase 3 MRCT post-hoc analysis and the post-market hard-to-heal cases of the DFU new drug, Fespixon have been accepted for an oral presentation at European Wound Management Association (EWMA) 2023. (2)The European Wound Management Association (EWMA) was founded in 1991. Every year, EWMA attracts over 3,000 health professional participants from more than 80 countries. Any other matters that need to be specified:The presentation slides will be uploaded to Market Observation Post System according to the regulation.

↑

關閉

建議您使用以下瀏覽器觀看合一網站，
以獲得最佳瀏覽效果。

要下載瀏覽器，請直接點擊以下:

IE瀏覽器現已不支援大多數網站，並將於2022年6月終止服務

如何使用IE找到Microsoft Edge?

開啟新分頁(紅色框)
於搜尋框中打入Edge(紅色框)，並按搜尋(藍色框)
點擊【立即啟動】(藍框處)打開 Microsoft Edge